Roggwil, March 31, 2020 – Resaphene Suisse AG, ISIN CH0367465439, WKN A2JG91, announced on 30.03.2020 the withdrawal of its inclusion in the Vienna MTF at the Vienna Stock Exchange in accordance with § 10 of the Conditions for the operation of the Vienna MTF, and the last trading day will be April 30, 2020. In negotiations with investors, the inclusion in the Vienna MTF proved to be an obstacle for investment from private equity funds. The management board is now addressing this by executing a Going Private.

Currently, the first quarter is developing into the best quarter in the company's history at the group level. This year, the FDA approval is to be obtained to bring the tinnitus therapy device tinniwell to market in the USA.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Roggwil, Switzerland, is a medical technology company founded in 2015 that has been selling a tinnitus therapy device under the name tinniwell since 2016. Since June 2018, the shares have been traded on the Vienna Stock Exchange in the Vienna MTF segment. The Resaphene Deutschland GmbH in Constance, Resaphene UK Ltd. in London, and Resaphene US LLC
in the USA also act as further sales companies.

++ Contact for inquiries:

Resaphene Suisse AG
Bahnhofplatz 5
9322 Egnach
Switzerland

Investor Relations Contact:
Ms. Anke Rauterkus (Chief Executive Officer)
a.rauterkus@resaphene.ch